论文部分内容阅读
目的:探讨肝细胞生长因子(HGF)在乳腺癌组织中的表达水平变化及与患者远期预后、化疗敏感性的关系。方法:选取121例经病理学证实为浸润性乳腺癌的患者,采用免疫组化染色方法观察术前未接受放化疗治疗的55例乳腺癌患者癌组织中HGF的表达水平,分析术前接受新辅助化疗的66例浸润性乳腺癌患者中不同HGF表达情况与患者预后的关系;检测下调HGF后乳腺癌MCF-7细胞与表阿霉素共培养的细胞增殖情况。结果:121例浸润性乳腺癌患者有77例(63.64%)患者乳腺癌组织中HGF表达阳性;HGF表达阳性、阴性患者的肿瘤分化程度、TNM分期、淋巴结转移率有关(均P<0.05)。HGF阳性表达患者新辅助化疗缓解率明显低于阴性组的(50.00 vs.86.67%,P<0.05),5年存活率明显低于阴性患者的(63.98%,vs.86.67%,P<0.05);MCF-7细胞HGF表达下调后对表阿霉素的敏感性明显增高(P<0.05)。结论:HGF在乳腺癌组织中的表达与肿瘤分化程度、TNM分期、淋巴结转移相关,阳性表达会影响患者的化疗效果,下调HGF表达可增强乳腺癌细胞对化疗的敏感性。
Objective: To investigate the expression of hepatocyte growth factor (HGF) in breast cancer and its relationship with long-term prognosis and chemosensitivity. Methods: Totally 121 patients with pathologically confirmed invasive breast cancer were selected. The expression of HGF in 55 cases of breast cancer without radiotherapy and chemotherapy before operation was observed by immunohistochemistry. Adjuvant chemotherapy in 66 cases of invasive breast cancer patients with different HGF expression and prognosis of patients; detection of down-regulation of breast cancer MCF-7 cells and epirubicin co-cultured cells proliferation. Results: The positive expression of HGF in breast cancer was found in 77 cases (63.64%) of 121 invasive breast cancer patients. The positive expression of HGF in breast cancer tissues was related to the degree of tumor differentiation, TNM stage and lymph node metastasis (all P <0.05). The response rate of neoadjuvant chemotherapy in HGF positive patients was significantly lower than that in negative patients (50.00 vs.86.67%, P <0.05), and the 5-year survival rate was significantly lower than that in negative patients (63.98% vs.86.67%, P <0.05) The sensitivity of epirubicin to MCF-7 cells was significantly increased (P <0.05). Conclusion: The expression of HGF in breast cancer is correlated with the degree of tumor differentiation, TNM stage and lymph node metastasis. The positive expression of HGF affects the chemotherapeutic effect in patients. Down-regulation of HGF expression can enhance the sensitivity of breast cancer cells to chemotherapy.